– USA, CA – Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of Dr. Pablo Cagnoni, M.D., to its board of directors, bringing to Synthekine extensive leadership experience in the biotech industry and a successful track record of oncology drug development.
“Synthekine has made significant advances in 2020, with our first programs on track for IND filings in 2021, and I am delighted to have Pablo join our board of directors and bring his considerable insights in developing breakthrough oncology products to support our continued progress,” said CEO, Dr. Debanjan Ray. “At the same time, our distinguished scientific advisory board will provide guidance as we apply our multiple cytokine engineering efforts to important targets for the treatment of cancer and autoimmune disease.”
The company also announced the formation of its scientific advisory board to help guide the extensive cytokine engineering efforts. The scientific advisory board will support the company as it advances its cytokine therapeutic programs and synthekine platform.
The SAB is chaired by Synthekine’s Scientific Founder, Dr. Christopher Garcia, Ph.D., and the members are:
- Dr. Christopher Garcia, Ph.D., Professor of Molecular and Cellular Physiology and Structural Biology at Stanford University School of Medicine, a Howard Hughes Medical Institute investigator, and a member of both the National Academy of Sciences and the National Academy of Medicine. (Chair),
- Dr. Christopher Hunter, Ph.D., Professor of Pathobiology at the University of Pennsylvania School of Veterinary Medicine,
- Dr. Nils Lonberg, Ph.D., biopharma veteran and member of Synthekine’s board of directors,
- Dr. Casey Weaver, M.D., Professor of Pathology at the University of Alabama at Birmingham,
- Dr. John Wherry, Ph.D., Department Chair of Systems Pharmacology and Translational Therapeutics and Director of the University of Pennsylvania Institute for Immunology.
About Dr. Pablo Cagnoni
Dr. Cagnoni has led the development, approval, and/or commercialization of more than twenty approved medicines. He is currently the CEO of Rubius Therapeutics, a clinical-stage biotech company developing genetically engineered red blood cells to treat various cancers and autoimmune diseases. Before Rubius, Dr. Cagnoni served as the President and CEO of Tizona Therapeutics. Previously, he was President of Onyx Pharmaceuticals, where he led efforts from early product development to commercialization of the full portfolio. Dr. Cagnoni has had several clinical development leadership roles in his past, including Global Head of Clinical Development at Novartis Oncology, CMO at Allos Therapeutics, and CMO at OSI Pharmaceuticals.
“Synthekine is built on remarkable cytokine research and I have been truly impressed with how effectively the team is advancing its diverse pipeline and platforms,” said Dr. Cagnoni. “I feel a shared affinity for their mission to bring these new treatments to patients in need, and I look forward to supporting the company’s advancement into the clinic and broadening of cytokine therapeutic concepts.”
About Synthekine
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.
For more information: https://www.synthekine.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
